What: Shares of Array BioPharma (NASDAQ: ARRY ) , a biopharmaceutical company focused on developing novel small molecule cancer drugs, surged just shy of 10% on Monday following a hefty price target hike from brokerage firm Stifel Nicolaus.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Brokerage firm Jefferies maintains its rating on Array Biopharma Inc (NASDAQ:ARRY). As per the latest information, the brokerage house raises the price target to $9 per share from a prior target of $7.
... finishing just above the breakeven mark. However, while most sectors were in the red today, Starbucks Corporation (NASDAQ:SBUX), Pandora Media Inc (NYSE:P) and Array Biopharma Inc (NASDAQ:ARRY) beat the market by a mile to sit among the day's ...
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.